Eloxx Pharmaceuticals Inc. (ELOX) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $13.45 (+1.89% 1D, market cap $53.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ELOX ranks #483 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ELOX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INKT (MiNK Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $55.5M) and KLRS (Kalaris Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $50.7M). Among the 5-stock peer group, ELOX leads on earnings multiple (N/A) while ELOX leads on capital efficiency (-35.0% ROIC).
Per ELOX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001035354), Eloxx Pharmaceuticals Inc. generated $0 in revenue (-100.0% YoY), -$6.0M in net income, and -$6.3M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 35% of 52W Range • RSI-14 at 45.4 (NEUTRAL RANGE)
20D Institutional Volume Accumulation (±12.5% realized swing band)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While ELOX currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($15.34) and Max Pain ($14.12) forces dealer call-delta covering toward $24.57.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Eloxx Pharmaceuticals Inc. (ELOX) advanced +1.89% to $13.45, trading at 35% of its 52-week range ($8.2 – $23.4). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Eloxx Pharmaceuticals Inc. (ELOX) market action, institutional positioning, and fundamental catalysts.
Stocktwits report covering Eloxx Pharmaceuticals Inc. (ELOX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Eloxx Pharmaceuticals Inc. (ELOX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Eloxx Pharmaceuticals Inc. (ELOX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Eloxx Pharmaceuticals Inc. (ELOX) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Eloxx Pharmaceuticals Inc. (ELOX) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Eloxx Pharmaceuticals Inc. (ELOX) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Eloxx Pharmaceuticals Inc. (ELOX) market action, institutional positioning, and fundamental catalysts.
Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a clinical-stage biopharmaceutical company developing exaluren for the treatment of rare kidney diseases, today announced that the U.S. Food and Drug Administration (FDA) has c
Guggenheim analyst Vamil Divan maintains Eloxx Pharma (NASDAQ:ELOX) with a Buy and lowers the price target from $43 to $40.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ELOX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ELOX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Eloxx Pharmaceuticals Inc. (ELOX) ranks #483 by composite RQD confidence (42/100, grade D-) and #741 by equity capitalization ($53.3M). Within this direct 5-issuer industry benchmark cohort, ELOX leads on earnings valuation at N/A trailing P/E, while ELOX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. INKT currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with ELOX at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ELOX
ACTIVE
Eloxx Pharmaceuticals Inc. | D- | 42/100 | — | — | -35.0% | +1.89% | $53.3M | Benchmark Subject |
| INKT MiNK Therapeutics Inc. | D- | 43/100 | — | — | -35.0% | -3.17% | $55.5M | /inkt-vs-elox → |
| KLRS Kalaris Therapeutics Inc. | E | 31/100 | — | — | -35.0% | -4.69% | $50.7M | /klrs-vs-elox → |
| CRBU Caribou Biosciences Inc. | E | 33/100 | — | — | -35.0% | -4.90% | $47.7M | /crbu-vs-elox → |
| TIL Instil Bio Inc. | D- | 39/100 | — | — | -35.0% | -0.37% | $46.3M | /til-vs-elox → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Eloxx Pharmaceuticals Inc. (ELOX) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $6.4M ) , GAAP net income of -$6.0M, operating cash flow of -$6.3M, and free cash flow of -$6.3M (-34.2% YoY). On the balance sheet, ELOX closed FY2025 with $5.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$6.0M | -$6.3M | -$6.3M | $5.3M | $0 |
| FY2024 (FY) | 2024-12-31 | $6.4M | -$3.1M | -$4.7M | -$4.7M | $3.0M | $0 |
| FY2023 (FY) | 2023-12-31 | $0 | -$17.1M | -$14.3M | -$14.3M | — | — |
As of 2026-11-02, Eloxx Pharmaceuticals Inc. (NASDAQ: ELOX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $13.45 (+1.89% 1D, market cap $53.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ELOX ranks #483 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ELOX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, INKT (MiNK Therapeutics Inc.) holds a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $55.5M) and KLRS (Kalaris Therapeutics Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $50.7M). Among the 5-stock peer group, ELOX leads on earnings multiple (N/A) while ELOX leads on capital efficiency (-35.0% ROIC).
Per ELOX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001035354), Eloxx Pharmaceuticals Inc. generated $0 in revenue (-100.0% YoY), -$6.0M in net income, and -$6.3M in free cash flow against $5.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ELOX last traded at $13.45 (+1.89% on volume of 13,999 shares), positioning the stock -12.32% below its 50-day simple moving average ($15.34) and -8.44% below its 200-day simple moving average ($14.69). Across its 52-week range of $8.20 to $23.40, ELOX sits at the 34.5% percentile with a 14-day RSI of 45.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.77 to $15.13).
Why ELOX Stock advanced +1.89% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ELOX scores 42 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:
Taken together, the investor implication is that the upside case rests on a turnaround in cash generation and institutional or insider conviction, both of which are currently weak in the source data. The valuation tradeoff is that a $53.3M market capitalization against negative ROIC and FCF yield leaves little demonstrated earnings support, so price moves are more likely to be driven by news flow and sentiment than by fundamentals. The 52-week range of $8.2 - $23.4 against the current $13.45 price illustrates this volatility.
Eloxx Pharmaceuticals Inc. (ELOX) is listed on NASDAQ in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the company profile, the market capitalization is $0.1B. Per the SEC financials, the company reported $0.0M revenue for FY 2025, so the source data does not establish a current product or customer base. Per the company profile, the business is classified as a biotechnology issuer; the source data does not describe specific products, customers, or revenue-generation mechanics.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-6.4M | $-6.0M | N/A | $-6.3M | $4.8M | $0.0M |
| FY 2024 | $6.4M | $-2.5M | $-3.1M | N/A | $-4.7M | $0.1M | $0.0M |
| FY 2023 | $0.0M | $-17.3M | $-17.1M | N/A | $-14.3M | N/A | N/A |
Per the SEC financials, the company reported operating and net losses across all three listed periods, with gross, operating, and net margins shown as 0% in the market data. Per the market data, ROIC is -35% and the Roarable RQD rating cites a Piotroski F-Score of 1/9 and an Altman Z-Score of 2.5. Per the SEC financials, FY 2025 cash is $4.8M against $0.0M of reported debt, while FY 2024 cash is $0.1M; the source data does not report FY 2023 cash or debt.
Real-time company headlines, analyst actions, and sector developments for Eloxx Pharmaceuticals Inc. (ELOX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Eloxx Pharmaceuticals Inc. (ELOX) market action, institutional positioning, and fundamental catalysts.
Stocktwits report covering Eloxx Pharmaceuticals Inc. (ELOX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering Eloxx Pharmaceuticals Inc. (ELOX) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering Eloxx Pharmaceuticals Inc. (ELOX) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Eloxx Pharmaceuticals Inc. (ELOX) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Eloxx Pharmaceuticals Inc. (ELOX) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Eloxx Pharmaceuticals Inc. (ELOX) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Eloxx Pharmaceuticals Inc. (ELOX) market action, institutional positioning, and fundamental catalysts.
Welcome to the ELOX (Eloxx Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 42/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ELOX, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Eloxx Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ELOX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $13.45 (52-wk range $8.20 - $23.40), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).